Clinical Trials Logo

Filter by:
  • Available  
  • Page [1]
NCT ID: NCT05067166 Available - Clinical trials for Hemorrhagic Fever, Ebola

Open-Label Expanded Access for Ebola-Infected Patients to Receive Human mAb Ansuvimab as Therapeutic or for HR PEP

Start date: n/a
Phase:
Study type: Expanded Access

The human monoclonal antibody (mAb), ansuvimab (mAb114), will be provided to Ebola-infected patients as either a treatment or as PEP under expanded access. Ansuvimab is administered at 50 mg/kg as a single intravenous (IV) infusion